Innovent Biologics (信达生物) IPO: A Major PD-1 MAb Competitor Might Have Just Emerged (Part 1)
Innovent Biologics is raising up to USD 500 million via a listing on the Hong Kong Stock Exchange. In this insight, we will discuss the following...
660 Views
Ascletis Pharma IPO Preview: Drug-Fuelled Euphoria Needed to Justify Valuation
Ascletis Pharma Inc (AP HK) which specialises in developing drugs to treat HCV (hepatitis C virus), HIV and liver cancer, is the first pre-profit...
746 Views
Trade Risks Start to Impact, as China Biotech Ambitions Grow…
Cyclical indicators are softening this month - new orders index for the Philly Fed fell nearly 23 points while Japan’s PMI new export orders...
129 Views
WuXi Biologics: Pass on This Valuation
The company's underwriters have announced a price range of HK$18.60 - HK$20.60 which implies a market cap of US$2.7-3.0 billion. We recommend...
749 Views
3SBio: A Leading, Pure-Play Chinese (HK-Listed) Biotechnology Company (Part II)
This is the part II of collaboration on 3SBio Inc (1530 HK) between Dr. Bhavneesh Sharma, MD, MBA and Luan NguyenDCF analysisWe have performed a...
339 Views